At Natera, DNA is in our blood

Natera™ is a global leader in cell-free DNA testing, with a focus on women's health, oncology, and organ health. Our mission is to change the management of disease worldwide by using a simple blood draw to proactively inform treatment.

natera™

Revolutionizing the standard of care with next-generation cell-free DNA testing

WOMEN'S HEALTH

A one-stop shop for the top-performing tests in women's health

Natera pioneered the use of cell-free DNA (cfDNA) technology in non-invasive prenatal testing (NIPT), products of conception (POC) analysis, and pre-implantation genetic screening.

With the 2020 launch of Empower, Natera's hereditary cancer screening test rounds out a one-stop shop for high-quality women's health tests.

Our tests:

Panorama - Next-generation NIPT
Horizon - Advanced carrier screening
Empower - Hereditary cancer test
Spectrum - Preimplantation genetics
Vistara - Single-gene NIPT
Anora - Miscarriage test (POC)



2M+ tests
#1 NIPT test on the market

>13,000 SNPs
analyzed in every NIPT test

ONCOLOGY

The first tumor-specific assay for truly individualized cancer care

Building on our leadership in cfDNA, Natera developed Signatera, the first and only custom-built circulating tumor DNA (ctDNA) test based on the unique tumor mutations of each patient.

Signatera's personalized, tumor informed assay is built to detect molecular residual disease (MRD), providing a predictive marker of relapse risk many months earlier than standard imaging or monitoring can reveal.

Our tests:

Signatera - Residual disease test (MRD)

>98% of MRD
positive patients will relapse without further treatment[1-4]

Up to 16 months
earlier detection of recurrence over a traditional CT scan[1-4]

ORGAN HEALTH

Unique innovation in mitigating kidney disease and transplant failure

Natera again extended its proprietary cfDNA technology platform to develop Prospera, the market's most precise cfDNA tool for early, clinically meaningful rejection assessment.

Prospera uses third-generation cfDNA technology to measure the amount of donor-derived cfDNA (dd-cfDNA) in a recipient's blood—resulting in best-in-class accuracy. Prospera is the only published test to identify T cell-mediated rejection (TCMR), the most common rejection in first year post-op.

In 2020 Natera launched Renasight, a test to determine if there is a genetic cause for an individual's kidney disease or if there is increased risk due to family history.

Our tests:

Prospera - Transplant assessment
Renasight - Kidney gene panel



~3x fewer
rejections missed, compared to first generation dd-cfDNA technologies[5-6]

89% more accurate
and sensitive than other competing tests[5-6]

natera™

The Natera Difference

At Natera, a test is more than just a test; it's part of an integrated experience, built to support our customers and to make testing easy

65+ genetic experts

100+ clinicians, PhDs, and scientists

CAP/CLIA certified

90 countries worldwide

Mobile blood-draw networks

Proactive patient outreach

NateraSync direct to your EMR

Broad in-network coverage

A track record of innovation and growth driven by cell-free DNA technology leadership



1. Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5(8):1124-1131.
2. Coombes RC, Page K, Salari R, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019;25(14):4255-4263.
3. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446-451.
4. Christensen E, Birkenskamp-Demtroder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019;37(18):1547-1557.
5. Sigdel TK, Archila FA, Constantin T, et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. J Clin Med. 2019;8(1):19.
6. Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol. 2017;28(7):2221-2232. doi: 10.1681/ASN.2016091034.

201 Industrial Road, Suite 410 | San Carlos, CA 94070 | Main +1 650.249.9090 | Fax 1.650.730.2272 | natera.com

natera™